Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Principal Investigator: Michael Altaweel, MD, MPH
Study Coordinator: Angie Adler
This study will determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with CRVO, with the primary outcome of visual acuity measured at 6 months.
Patients will be randomly assigned to one out of two study treatment groups. The study will compare aflibercept (2 mg) every 4 weeks to bevacizumab (1.25 mg) every 4 weeks.
Diagnosis and Key Eligibility Criteria:
At least 18 years of age with center-involved macular edema secondary to CRVO in the study eye. Previous treatment with anti-VEGF therapy is allowed with a 2 month washout period. Previous investigational therapy is allowed with some restrictions.
Duration of study: Approximately 1 year.
For more information, contact Angie Adler 608-265-7557.